These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 11858493

  • 1. Paradoxical platelet activation was not observed on dissociation of abciximab from GpIIb-IIIa complexes.
    Ndoko S, Poujol C, Combrié R, Nurden A, Nurden P.
    Thromb Haemost; 2002 Feb; 87(2):317-22. PubMed ID: 11858493
    [Abstract] [Full Text] [Related]

  • 2. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M, Ruf A, Pogatsa-Murray G, Dickfeld T, Rüdiger S, Taubitz W, Fischer J, Müller I, Meier D, Patscheke H, Schömig A.
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [Abstract] [Full Text] [Related]

  • 3. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F, Rossi E, Pareti FI, Colli S, Tremoli E, Gallo L.
    Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
    [Abstract] [Full Text] [Related]

  • 4. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M, Ruf A, Neumann FJ, Pogátsa-Murray G, Dickfeld T, Zohlnhöfer D, Schömig A.
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [Abstract] [Full Text] [Related]

  • 5. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ, Taatjes DJ, Sobel BE.
    Cardiovasc Res; 2000 Jan 14; 45(2):437-46. PubMed ID: 10728364
    [Abstract] [Full Text] [Related]

  • 6. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
    Straub A, Wendel HP, Azevedo R, Ziemer G.
    Eur J Cardiothorac Surg; 2005 Apr 14; 27(4):617-21. PubMed ID: 15784360
    [Abstract] [Full Text] [Related]

  • 7. [Conformational changes of the platelet membrane glycoprotein IIb-IIIa complex stimulated by a monoclonal antibody to the N-terminal segment of glycoprotein IIIa].
    Khaspekova SG, Vyzova TV, Lukin VV, Tikhomirov OIu, Berndt M, Kouns W, Mazurov AV.
    Biokhimiia; 1996 Mar 14; 61(3):412-28. PubMed ID: 8724599
    [Abstract] [Full Text] [Related]

  • 8. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
    Quinn MJ, Murphy RT, Dooley M, Foley JB, Fitzgerald DJ.
    J Pharmacol Exp Ther; 2001 May 14; 297(2):496-500. PubMed ID: 11303035
    [Abstract] [Full Text] [Related]

  • 9. Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin.
    Schneider DJ, Baumann PQ, Holmes MB, Taatjes DJ, Sobel BE.
    Thromb Haemost; 2001 Feb 14; 85(2):309-13. PubMed ID: 11246553
    [Abstract] [Full Text] [Related]

  • 10. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates.
    Marciniak SJ, Mascelli MA, Furman MI, Michelson AD, Jakubowski JA, Jordan RE, Marchese PJ, Frelinger AL.
    Thromb Haemost; 2002 Jun 14; 87(6):1020-5. PubMed ID: 12083481
    [Abstract] [Full Text] [Related]

  • 11. Activating effects of GPIIb/IIIa blockers: an intrinsic consequence of ligand-mimetic properties.
    Peter K, Schwarz M, Bode C.
    Circulation; 2002 May 28; 105(21):E180-1. PubMed ID: 12034670
    [No Abstract] [Full Text] [Related]

  • 12. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties.
    Suzuki K, Sato K, Kamohara M, Kaku S, Kawasaki T, Yano S, Iizumi Y.
    Biol Pharm Bull; 2002 Aug 28; 25(8):1006-12. PubMed ID: 12186399
    [Abstract] [Full Text] [Related]

  • 13. Expression of markers of platelet activation and the interpatient variation in response to abciximab.
    Bihour C, Durrieu-Jaïs C, Macchi L, Poujol C, Coste P, Besse P, Nurden P, Nurden AT.
    Arterioscler Thromb Vasc Biol; 1999 Feb 28; 19(2):212-9. PubMed ID: 9974400
    [Abstract] [Full Text] [Related]

  • 14. Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab): flow and endocytic mechanisms contribute to the transport.
    Nurden P, Poujol C, Durrieu-Jais C, Winckler J, Combrié R, Macchi L, Bihour C, Wagner C, Jordan R, Nurden AT.
    Blood; 1999 Mar 01; 93(5):1622-33. PubMed ID: 10029591
    [Abstract] [Full Text] [Related]

  • 15. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
    Matzdorff A, Voss R.
    Thromb Res; 2006 Mar 01; 117(3):307-14. PubMed ID: 15894353
    [Abstract] [Full Text] [Related]

  • 16. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists.
    Quinn M, Deering A, Stewart M, Cox D, Foley B, Fitzgerald D.
    Circulation; 1999 May 04; 99(17):2231-8. PubMed ID: 10226086
    [Abstract] [Full Text] [Related]

  • 17. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor--results from patients with acute myocardial infarction and healthy controls.
    Reininger AJ, Agneskirchner J, Bode PA, Spannagl M, Wurzinger LJ.
    Thromb Haemost; 2000 Feb 04; 83(2):217-23. PubMed ID: 10739376
    [Abstract] [Full Text] [Related]

  • 18. In vitro efficacy of platelet glycoprotein IIb/IIIa antagonist in blocking platelet function in plasma of patients with heparin-induced thrombocytopenia.
    Mak KH, Kottke-Marchant K, Brooks LM, Topol EJ.
    Thromb Haemost; 1998 Dec 04; 80(6):989-93. PubMed ID: 9869172
    [Abstract] [Full Text] [Related]

  • 19. MK-383 (tirofiban) induces a GPIIb/IIIa receptor conformation which differs from the resting and activated receptor.
    Barlage S, Wimmer A, Pfeiffer A, Rothe G, Schmitz G.
    Platelets; 2002 May 04; 13(3):133-40. PubMed ID: 12180495
    [Abstract] [Full Text] [Related]

  • 20. A novel mechanism for exposure of fibrinogen binding sites on GPIIb-IIIa by a monoclonal antibody.
    Hato T, Watanabe A, Nakatani S, Minamoto Y, Fujita S.
    Thromb Haemost; 1995 Jan 04; 73(1):138-43. PubMed ID: 7537917
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.